Posted by Michael Wonder on 25 Jul 2025
Trixeo Aerosphere receives positive EU CHMP opinion as first inhaled medicine using next-generation propellant with near-zero Global Warming Potential
25 July 2025 - Next-generation propellant offers 99.9% reduction in global warming potential compared to current propellants.
AstraZeneca’s Trixeo Aerosphere, already licensed for the treatment of chronic obstructive pulmonary disease in adults, has received a positive opinion from the CHMP of the EMA, endorsing it for use in the European Union with an innovative, next-generation propellant with near zero global warming potential.
